Ipamorelin vs GHRP-6 vs GHRP-2: A Research Comparison

July 24, 2026 • 6 min read • Blog

Ipamorelin, GHRP-6, and GHRP-2 are three synthetic growth hormone secretagogues (GHSs) that share a common target: the growth hormone secretagogue receptor type 1a (GHS-R1a), better known since 1999 as the ghrelin receptor. All three provoke a pulse of growth hormone (GH) from the anterior pituitary, yet they differ sharply in selectivity, potency per dose, appetite effects, and how far each has progressed through formal development. This comparison is aimed at researchers and reference readers trying to understand how these closely related peptides diverge on paper.

People typically search this trio because the compounds are constantly cross-referenced with one another: GHRP-6 was the founding molecule of the class, GHRP-2 was engineered to be more potent, and Ipamorelin was designed to strip away the off-target hormone release that the earlier two carry. Understanding that lineage is the fastest way to understand the differences.

Research-only notice. Ipamorelin, GHRP-6, and GHRP-2 are experimental research compounds. None is approved as a therapeutic in the United States, and this article is an educational reference only. It is not medical advice and describes laboratory and clinical-research findings, not guidance for personal use. Most human data are limited or historical.

Feature Ipamorelin GHRP-6 GHRP-2
Class/type Synthetic pentapeptide GH secretagogue (ghrelin-receptor agonist) Synthetic hexapeptide GH secretagogue; first-generation GHRP Synthetic hexapeptide GH secretagogue; second-generation GHRP (pralmorelin)
Mechanism Selective GHS-R1a agonist; Gq/11 → PLC → IP3 → Ca²⁺ → GH exocytosis GHS-R1a agonist at pituitary and hypothalamus; synergizes with GHRH GHS-R1a agonist at pituitary and hypothalamus; high GH pulse amplitude per dose
Half-life Short-acting; serum half-life reported ~2 h Short-acting; bi-exponential, elimination ~0.25–2.5 h across reports Short-acting; terminal half-life ~0.5 h in a pediatric PK study
Regulatory status Not approved; preclinical/experimental research compound Not approved; historical research and diagnostic-research tool Approved in Japan (2004) as a GH-deficiency diagnostic; not approved as a therapeutic
Evidence level Mostly preclinical (swine, rodent); limited human data Extensive 1980s–90s animal and early human research; no therapeutic approval Strongest clinical-development pedigree of the three; Phase I–II data exist
Primary research focus Selective GH release; GH-axis and bone/metabolic models GH release plus orexigenic (appetite) and ghrelin-signaling research Potent GH stimulation; diagnostic GH-deficiency testing

Mechanism: one receptor, three profiles

All three peptides bind GHS-R1a, a G-protein-coupled receptor concentrated in the hypothalamus and pituitary. Activation drives a Gq/11 → phospholipase C → IP3 cascade that mobilizes intracellular calcium and triggers exocytosis of stored GH from somatotrophs. GHRP-6 and GHRP-2 act at both hypothalamic and pituitary sites and can act synergistically with growth hormone-releasing hormone (GHRH), which works through a separate receptor. Because the two pathways converge at the pituitary, GHS peptides and GHRH combined produce a larger GH pulse than either alone.

GHRP-6 has outsized historical importance here. Cyril Bowers and colleagues characterized it in 1984 (Bowers et al., Endocrinology), and it was the synthetic ligand that ultimately led to the cloning of the GHS receptor by Howard et al. in 1996 and the discovery of its natural ligand, ghrelin, by Kojima et al. in 1999 — a textbook case of “reverse pharmacology.” That is why GHRP-6 is often used as a research probe of ghrelin signaling itself, not merely as a GH-releasing agent.

The pivotal distinction is selectivity. GHRP-6 and GHRP-2 do not release GH cleanly: both can raise adrenocorticotropic hormone (ACTH), cortisol, and prolactin, and GHRP-6 in particular is a strong orexigen. Ipamorelin was engineered to remove those liabilities. In the founding study (Raun et al., 1998), the pentapeptide matched GHRP-6 for GH-releasing potency but did not significantly elevate ACTH, cortisol, prolactin, FSH, LH, or TSH even at doses roughly 200 times the effective GH dose — a selectivity resembling GHRH. GHRP-2 sits between the two: highly potent per dose, with milder appetite effects than GHRP-6 but still measurable ACTH/cortisol activation.

Evidence and development status

These three peptides are at very different points on the development curve. GHRP-6 is the oldest and most studied as a discovery tool; decades of animal and early human work exist, but it was never advanced to therapeutic approval. GHRP-2 (pralmorelin, also coded KP-102 and GPA-748) went furthest clinically: it carried Phase I and Phase II programs for GH deficiency and short stature, and in 2004 Japan’s regulator approved pralmorelin as a diagnostic agent to assess GH-deficiency — making GHRP-2 the only member of this class to earn any regulatory approval, though as a test, not a treatment. US therapeutic development was discontinued.

Ipamorelin is the newest and, paradoxically, the least clinically advanced despite its attractive selectivity. Its evidence base is dominated by preclinical models, and human clinical data remain limited. It is best characterized as an experimental research compound rather than a therapeutic candidate with mature human trials. Across all three, readers should treat marketing-style efficacy claims skeptically; the robust findings concern receptor pharmacology and GH-pulse dynamics, not validated human outcomes.

Research context

In practice, investigators reach for different members of this trio for different questions. GHRP-6 suits work that actually involves ghrelin signaling, appetite, or gut-brain effects, because its orexigenic activity is a feature rather than a nuisance. GHRP-2 is the choice where a strong, reproducible GH pulse per dose is wanted — hence its diagnostic role. Ipamorelin is selected to isolate GH release from confounding cortisol, prolactin, or hunger responses, making it a cleaner probe of the GH axis in bone, body-composition, and metabolic models.

Key differences

  • Selectivity: Ipamorelin releases GH without meaningfully raising ACTH, cortisol, or prolactin; GHRP-6 and GHRP-2 both activate those axes to varying degrees.
  • Appetite: GHRP-6 is a potent orexigen; GHRP-2 stimulates appetite less; Ipamorelin has minimal appetite effect.
  • Potency per dose: GHRP-2 produces some of the highest GH pulse amplitudes per unit dose in the class; Ipamorelin is comparable to GHRP-6.
  • Peptide length: Ipamorelin is a pentapeptide (five residues); GHRP-6 and GHRP-2 are hexapeptides (six residues).
  • Regulatory footprint: Only GHRP-2 (pralmorelin) holds any approval — a Japanese diagnostic authorization — while Ipamorelin and GHRP-6 remain unapproved research compounds.
  • Historical role: GHRP-6 is the founding molecule that led to discovery of the GHS receptor and ghrelin; the others are later, more targeted designs.

Which for what research?

Framed strictly as research tools, the three map onto distinct questions. Ipamorelin is the most selective probe of GH release, useful when a study needs to attribute effects to GH without cortisol, prolactin, or appetite confounds. GHRP-6 is the reference ghrelin-mimetic for work engaging appetite and broader ghrelin-receptor biology, and it carries the deepest historical literature. GHRP-2 is the potency and diagnostics choice: it drives large, consistent GH pulses per dose and is the only one of the three with a formal (diagnostic) regulatory footing. There is no “best” peptide in the abstract — only a best fit for a specified research aim, within the research-only limits noted above.

Put these side by side in the Compare Peptides tool.

What is the main difference between Ipamorelin and GHRP-6 or GHRP-2?

Selectivity. Ipamorelin releases growth hormone with little to no rise in ACTH, cortisol, or prolactin and minimal appetite stimulation, whereas GHRP-6 and GHRP-2 activate those additional pathways — GHRP-6 most notably through strong, short-lived hunger.

Are any of these three approved for human use?

Not as therapeutics. GHRP-2 (pralmorelin) was approved in Japan in 2004 as a diagnostic agent for assessing growth hormone deficiency, which is the only regulatory approval in the class. Ipamorelin and GHRP-6 remain unapproved research compounds.

Why is GHRP-6 historically important?

GHRP-6 was the first synthetic growth hormone-releasing peptide (Bowers, 1984). Studying how it worked led researchers to clone the GHS receptor in 1996 and then discover its natural ligand, ghrelin, in 1999 — an example of “reverse pharmacology.”

How long do these peptides act?

All three are short-acting. Reported half-lives are on the order of tens of minutes to a couple of hours — roughly 0.5 h for GHRP-2 in one pediatric study, a bi-exponential profile for GHRP-6, and around 2 h for Ipamorelin. The GH pulse each triggers is likewise transient.

Which produces the strongest growth hormone pulse?

Per unit dose, GHRP-2 is generally reported to generate some of the highest GH pulse amplitudes of the class, which is part of why it was developed for diagnostic GH-stimulation testing. Ipamorelin’s potency is comparable to GHRP-6.

Sources

  • Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. PMID 9849822
  • Bowers CY, Momany FA, Reynolds GA, Hong A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 1984;114(5):1537-45. PMID 6714155
  • Furuta S, Shimada O, Doi N, et al. General pharmacology of KP-102 (GHRP-2), a potent growth hormone-releasing peptide. Arzneimittelforschung. 2004;54(12):868-80. PMID 15646371
  • Pihoker C, Kearns GL, French D, Bowers CY. Pharmacokinetics and pharmacodynamics of growth hormone-releasing peptide-2: a phase I study in children. J Clin Endocrinol Metab. 1998;83(4):1168-72. PMID 9543135
  • Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-7. PMID 8688086
  • Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656-60. PMID 10604470